PD-L1 Expression of the Residual Tumor Serves as a Prognostic Marker in Local Advanced Breast Cancer After Neoadjuvant Chemotherapy

International Journal of Cancer - United States
doi 10.1002/ijc.30552
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Erratum To: Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Breast Cancer and Its Clinical Significance

Breast Cancer Research
Cancer ResearchOncology
2017English

P058 Effects of Neoadjuvant Chemotherapy on the Expression of PD-L1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P53 Expression as a Prognostic Marker in Inflammatory Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Evaluation of Prognostic Factors and Validation of Tumor Response Ratios After Neoadjuvant Chemotherapy in Patients With Breast Cancer

Journal of Breast Disease
2016English

PD-L1 Expression in Triple-Negative Breast Cancer

Cancer immunology research
Cancer ResearchImmunology
2014English

PD-L1 Expression by Tumor Cell-Lines: A Predictive Marker in Melanoma

Experimental Dermatology
BiochemistryDermatologyMolecular Biology
2018English

Metabolic Nodal Response as a Prognostic Marker After Neoadjuvant Therapy for Oesophageal Cancer

British Journal of Surgery
Surgery
2017English

PD-L1 Expression Combined With Microsatellite Instability/Cd8+ Tumor Infiltrating Lymphocytes as a Useful Prognostic Biomarker in Gastric Cancer

Scientific Reports
Multidisciplinary
2019English

The Role of PD-L1 in the Prediction of Treatment Responses to Neoadjuvant Chemotherapy in Breast Carcinoma

Pathology
Forensic MedicinePathology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy